An oral PI-IMID regimen has shown ‘promising’ effectiveness and tolerability in patients with relapsed/refractory multiple myeloma (RRMM) and could be a more affordable option, an Australian study shows. Victorian researchers investigated the efficacy and tolerability of continuous ixazomib-thalidomide dexamethasone (ITd: 4 mg, day 1, 8, 15; 100 mg daily; and 40 mg weekly). A total of ...
Oral combination of ixazomib and thalidomide shows promising results in RRMM
By Sunalie Silva
27 May 2021